Cancer · 1994 · 161 citations · 43 references
MedicineOncologySurgeryOncologic SurgerySurgical OncologyTumor ImmunologyInterferon-based TherapyMalignant TumorsPleural MalignanciesPleural TumorsInitial BiopsyInterferon Gamma ResponseInterferon-gamma ResponsesMalignant Pleural Mesothelioma ImmunotherapyMesothelioma Systemic TherapyPleural Tumor TreatmentPrognostic Factors Analysis
BACKGROUND: This report presents the results of a prospective multi-institutional study of intrapleural treatment with gamma-interferon in patients with Butchart's Stages I and II epithelial or mixed malignant pleural mesothelioma. METHODS: Interferon was administered at a dose of 40 million units twice a week for 8 weeks intrapleurally via a catheter or an implantable port. Thoracoscopic or surgical biopsy was performed if computed tomography scan 2 weeks after the end of treatment demonstrated a reduction in tumor size. Survival was calculated after a follow-up of at least 18 months. Prognostic factors were identified by univariate and multivariate analyses (Cox model). RESULTS: Eighty-nine patients were included over 46 months. Eight histologically confirmed complete responses and nine partial responses with at least a 50% reduction in tumor size were obtained. The overall response rate was 20%. Most responses were achieved in patients with early stage disease. The response rate for patients with Stage I disease was 45%. Tolerance of interferon was good. Treatment was performed on an outpatient basis. The main side effects were hyperthermia, liver toxicity, neutropenia, and catheter-related infection. CONCLUSIONS: Gamma-interferon is effective mainly in Stage I mesothelioma, especially if the tumor is confined to the parietal or diaphragmatic pleura (Stage IA).
43
Carl Nathan, Henry W. Murray, Michael E. Wiebe et al. · The Journal of Experimental Medicine · 1983 · 2K citations · Full text
Alvan R. Feinstein, Daniel M. Sosin, Carolyn K. Wells · New England Journal of Medicine · 1985 · 1.6K citations
Medicine, Oncology, Metastasis +16
Analysis of survival by tumor response.
J R Anderson, Kevin C. Cain, RD Gelber · Journal of Clinical Oncology · 1983 · 1.1K citations
Medicine, Biostatistics, Oncology +15
Analysis of survival by tumor response.
J R Anderson, Robert B. Davis · Journal of Clinical Oncology · 1986 · 1K citations
Medicine, Biostatistics, Oncology +15
Expression of human immune interferon cDNA in E. coli and monkey cells
Patrick W. Gray, David W. M. Leung, Diane Pennica et al. · Nature · 1982 · 699 citations